Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
This study design is subject to relevant SFDA regulations about clinical trials. Patients
will be screened for inclusion into the study at the initial visit(240 patients to be
recruited) and then undergo a minimum of 3-7 day's placebo washout period(placebo wash out is
to eliminate the effect of prior antipsychotic medication with tablets without any active
ingredients)(patients without prior antipsychotic medication are exempt from the washout
phase). After screening and washout period, eligible patients will be randomly assigned to
the two treatment group, Aripiprazole or Risperidone, for 6 week's treatment. Patients will
be hospitalized for the entire duration of the study. Patients' condition will be assessed
weekly.